@article{a6e98c72dea7419487e8649706dff9bd,
title = "A protocol for the systematic review and meta-Analysis of studies in which cannabinoids were tested for antinociceptive effects in animal models of pathological or injury-related persistent pain",
abstract = "Introduction:The International Association for the Study of Pain has established a global task force to comprehensively investigate the use of cannabinoids and cannabis-based medicines for pain management. This systematic review, the first in this field, will assess the preclinical literature that investigates the antinociceptive effects of cannabinoids, cannabis-based medicines, and endocannabinoid system modulators in animal models of tissue damage, inflammation, or neuropathy.Methods:A systematic electronic search of 3 online databases will identify relevant studies in which cannabinoids, cannabis-based medicines, and endocannabinoid system modulators have been tested in animal models of injury-related or pathological persistent pain. Data will be extracted for pain-Associated behavioural outcomes, study design, and the reporting of measures to avoid bias. Standardised mean difference meta-Analysis will be used to provide summary estimates of efficacy, with the effects of study quality and study design explored using stratified meta-Analysis.Perspective:The evaluation of the preclinical evidence will quantify the antinociceptive effects of cannabinoids on pain behaviour in animal models of pathological pain in an effort to quantify the presence and prevalence of analgesic efficacy. It will also provide an understanding of the strengths and weaknesses of the preclinical field and inform an agenda for future research.",
keywords = "Animal models, Cannabinoids, Cannabis, Endocannabinoid system modulators, Pain, Systematic review",
author = "Nadia Soliman and Hohmann, {Andrea G.} and Simon Haroutounian and Kimberley Wever and Rice, {Andrew S.C.} and Finn, {David P.}",
note = "Funding Information: S. Haroutounian reports grants from Pfizer, Inc, and consulting fees from Medoc Ltd, outside the scope of the submitted work. K. Wever has nothing to declare. D.P. Finn reports grants from both public bodies and industry (Randox, Alkermes, and Shionogi) for research outside the scope of the submitted work. A.S.C. Rice is Chair of the task force and an IASP councillor. He reports consultancy and advisory board work for Imperial College Consultants–in the past 24 months, this has included remunerated work for Galapagos, Toray, Quartet, Lateral, Novartis, Pharmaleads, Cambridge University (Prof Peter McNaughton), Orion, Asahi Kasei, and Theranexus, outside the scope of the submitted work. In addition, A.S.C. Rice was the owner of share options in Spinifex Pharmaceuticals from which personal benefit accrued on the acquisition of Spinifex by Novartis in July 2015 and from which future milestone payments may occur. In addition, Dr Rice is named as an inventor on patents: A.S.C. Rice, Vandevoorde S., and Lambert D.M Methods using N-(2-propenyl)hexadecanamide and related amides to relieve pain. WO 2005/079771 and Okuse et al. Methods of treating pain by inhibition of vgf activity EP13702262.0/WO2013 110945. Publisher Copyright: Copyright {\textcopyright} 2019 The Author(s).",
year = "2019",
month = jul,
day = "1",
doi = "10.1097/PR9.0000000000000766",
language = "English",
volume = "4",
journal = "Pain Reports",
issn = "2471-2531",
number = "4",
}